Germany · Delayed Price · Currency is EUR Biofrontera AG Statistics
Total Valuation
Biofrontera AG has a market cap or net worth of EUR 14.52 million. The enterprise value is 10.78 million.
| Market Cap | 14.52M |
| Enterprise Value | 10.78M |
Important Dates
The last earnings date was Sunday, May 31, 2026.
| Earnings Date | May 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biofrontera AG has 6.08 million shares outstanding. The number of shares has decreased by -0.22% in one year.
| Current Share Class | 6.08M |
| Shares Outstanding | 6.08M |
| Shares Change (YoY) | -0.22% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.07 |
| PB Ratio | 0.85 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.96, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.96 |
| Quick Ratio | 2.07 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -42.21 |
Financial Efficiency
Return on equity (ROE) is -36.44% and return on invested capital (ROIC) is -6.49%.
| Return on Equity (ROE) | -36.44% |
| Return on Assets (ROA) | -1.96% |
| Return on Invested Capital (ROIC) | -6.49% |
| Return on Capital Employed (ROCE) | -4.39% |
| Weighted Average Cost of Capital (WACC) | 2.71% |
| Revenue Per Employee | 197,522 |
| Profits Per Employee | -35,406 |
| Employee Count | 74 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 0.55 |
Taxes
In the past 12 months, Biofrontera AG has paid 5.72 million in taxes.
| Income Tax | 5.72M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +0.84% in the last 52 weeks. The beta is -0.24, so Biofrontera AG's price volatility has been lower than the market average.
| Beta (5Y) | -0.24 |
| 52-Week Price Change | +0.84% |
| 50-Day Moving Average | 2.48 |
| 200-Day Moving Average | 2.59 |
| Relative Strength Index (RSI) | 43.49 |
| Average Volume (20 Days) | 1,413 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biofrontera AG had revenue of EUR 13.63 million and -2.44 million in losses. Loss per share was -0.40.
| Revenue | 13.63M |
| Gross Profit | 11.23M |
| Operating Income | -802,000 |
| Pretax Income | -955,000 |
| Net Income | -2.44M |
| EBITDA | -633,750 |
| EBIT | -802,000 |
| Loss Per Share | -0.40 |
Balance Sheet
The company has 5.64 million in cash and 1.89 million in debt, with a net cash position of 3.75 million or 0.62 per share.
| Cash & Cash Equivalents | 5.64M |
| Total Debt | 1.89M |
| Net Cash | 3.75M |
| Net Cash Per Share | 0.62 |
| Equity (Book Value) | 17.10M |
| Book Value Per Share | 2.81 |
| Working Capital | 8.77M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 168,250 |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 82.41%, with operating and profit margins of -5.88% and -17.93%.
| Gross Margin | 82.41% |
| Operating Margin | -5.88% |
| Pretax Margin | -7.01% |
| Profit Margin | -17.93% |
| EBITDA Margin | -4.65% |
| EBIT Margin | -5.88% |
| FCF Margin | n/a |
Dividends & Yields
Biofrontera AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.22% |
| Shareholder Yield | 0.22% |
| Earnings Yield | -16.82% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 14, 2024. It was a reverse split with a ratio of 0.047619.
| Last Split Date | May 14, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.047619 |
Scores
Biofrontera AG has an Altman Z-Score of -5.17 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.17 |
| Piotroski F-Score | 2 |